Gelatin-coated Silicon Oxide Nanoparticles Encapsulated Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Cardiac Cell Death Against an Simulated Ischaemia/reperfusion Injury

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Oct 9

PMID 37809945

Authors

Faprathan Pikwong

Chayanisa Phutiyothin

Wannapat Chouyratchakarn

Phornsawat Baipaywad

Podsawee Mongkolpathumrat

Sarawut Kumphune

Affiliations

Soon will be listed here.

Abstract

Ischemic Heart Disease (IHD) is the main global cause of death. Previous studies indicated that recombinant human secretory leukocyte protease inhibitor (rhSLPI) exhibits a cardioprotective effect against myocardial ischaemia/reperfusion (I/R) injury. However, SLPI has a short half-life due to digestion by protease enzymes in circulation. The application of nanoparticle encapsulation could be beneficial for SLPI delivery. Several types of nanoparticles have been developed to encapsulate SLPI and applied in some disease models. However, silica nanoparticles for rhSLPI delivery, particularly on myocardial I/R injury, have never been studied. In this study, we aimed to fabricate gelatin-covered silica nanoparticles (GSNPs) to encapsulate rhSLPI and cardioprotective effect of GSNP-SLPI against an simulated ischaemia/reperfusion (sI/R). Silica dioxide nanoparticles (SNPs) were fabricated followed by incubation with 0.33 mg/mL of rhSLPI. Then, SNPs containing rhSLPI were coated with gelatin (GSNPs). The GSNPs and rhSLPI-GSNPs were characterized by particle size, zeta potential, and morphology scanning electron microscope (SEM). The concentration of rhSLPI in rhSLPI-GSNPs and drug release was determined by ELISA. Then, cytotoxicity and cardioprotective effect were determined by incubation of GSNPs or rhSLPI-GSNPs with rat cardiac myoblast cell line (H9c2) subjected to simulated ischaemia/reperfusion (sI/R). The results showed the particle size of SNPs, GSNPs, and rhSLPI-GSNPs was 273, 300, and 301 nm, with a zeta potential of -57.21, -22.40, and -24.50 mV, respectively. One milligram of rhSLPI-GSNPs contains 235 ng of rhSLPI. The rhSLPI-GSNPs showed no cytotoxicity on cardiac cells. Treatment with 10 μg/ml of rhSLPI-GSNPs could significantly reduce sI/R induced cardiac cell injury and death. In conclusion, this is study to show successful of fabricating novel rhSLPI-encapsulating gelatin-covered silica nanoparticles (rhSLPI-GSNPs) and the cardioprotective effects of rhSLPI-GSNPs against cardiac cell injury and death from myocardial ischaemia/reperfusion.

References

Pawar N, Bohidar H . Surface selective binding of nanoclay particles to polyampholyte protein chains. J Chem Phys. 2009; 131(4):045103. DOI: 10.1063/1.3184803. View

Liao Y, Lee C, Chen S, Lai J, Wu K . Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma. J Mater Chem B. 2020; 5(34):7008-7013. DOI: 10.1039/c7tb01217a. View

Nernpermpisooth N, Prompunt E, Kumphune S . An endothelial cell protective effect of secretory leukocyte protease inhibitor against simulated ischaemia/reperfusion injury. Exp Ther Med. 2017; 14(6):5793-5800. PMC: 5740774. DOI: 10.3892/etm.2017.5272. View

Celermajer D, Chow C, Marijon E, Anstey N, Woo K . Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol. 2012; 60(14):1207-16. DOI: 10.1016/j.jacc.2012.03.074. View

McGarry N, M Greene C, McElvaney N, Weldon S, Taggart C . The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity. J Immunol Res. 2015; 2015:507315. PMC: 4515294. DOI: 10.1155/2015/507315. View

Zou Z, He D, He X, Wang K, Yang X, Qing Z . Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery. Langmuir. 2013; 29(41):12804-10. DOI: 10.1021/la4022646. View

Bergenfeldt M, Bjork P, Ohlsson K . The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest. 1990; 50(7):729-37. DOI: 10.1080/00365519009091066. View

Vinten-Johansen J . Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004; 61(3):481-97. DOI: 10.1016/j.cardiores.2003.10.011. View

Yang J, Zhu J, Sun D, Ding A . Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta. 2005; 1745(3):310-7. DOI: 10.1016/j.bbamcr.2005.07.006. View

10.

Gibbons A, McElvaney N, Taggart C, Cryan S . Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul. 2008; 26(6):513-22. DOI: 10.1080/02652040802466535. View

11.

Gast A, Anderson W, Probst A, Nick H, Thompson R, Eisenberg S . Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Am Rev Respir Dis. 1990; 141(4 Pt 1):889-94. DOI: 10.1164/ajrccm/141.4_Pt_1.889. View

12.

Mongkolpathumrat P, Nernpermpisooth N, Kijtawornrat A, Pikwong F, Chouyratchakarn W, Yodsheewan R . Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury. Front Cardiovasc Med. 2022; 9:976083. PMC: 9437585. DOI: 10.3389/fcvm.2022.976083. View

13.

Mongkolpathumrat P, Kijtawornrat A, Suwan E, Unajak S, Panya A, Pusadee T . Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion. Biomedicines. 2022; 10(5). PMC: 9138276. DOI: 10.3390/biomedicines10050988. View

14.

Imani R, Rafienia M, Emami S . Synthesis and characterization of glutaraldehyde-based crosslinked gelatin as a local hemostat sponge in surgery: an in vitro study. Biomed Mater Eng. 2013; 23(3):211-24. DOI: 10.3233/BME-130745. View

15.

Prompunt E, Nernpermpisooth N, Sanit J, Kumphune S . Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor (rhSLPI) reduces an in vitro ischemia/reperfusion injury in rat cardiac myoblast (H9c2) cell. Biomol Concepts. 2018; 9(1):17-32. DOI: 10.1515/bmc-2018-0004. View

16.

Kongpol K, Nernpermpisooth N, Prompunt E, Kumphune S . Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury. Biomolecules. 2019; 9(11). PMC: 6920779. DOI: 10.3390/biom9110678. View

17.

Taggart C, Lowe G, Greene C, Mulgrew A, ONeill S, Levine R . Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001; 276(36):33345-52. DOI: 10.1074/jbc.M103220200. View

18.

Mongkolpathumrat P, Kijtawornrat A, Prompunt E, Panya A, Chattipakorn N, Barrere-Lemaire S . Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury. Biomedicines. 2021; 9(4). PMC: 8070046. DOI: 10.3390/biomedicines9040422. View

19.

Sanit J, Prompunt E, Adulyaritthikul P, Nokkaew N, Mongkolpathumrat P, Kongpol K . Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats. Exp Ther Med. 2019; 18(3):1701-1714. PMC: 6676201. DOI: 10.3892/etm.2019.7763. View

20.

Prompunt E, Sanit J, Barrere-Lemaire S, Nargeot J, Noordali H, Madhani M . The cardioprotective effects of secretory leukocyte protease inhibitor against myocardial ischemia/reperfusion injury. Exp Ther Med. 2018; 15(6):5231-5242. PMC: 5996700. DOI: 10.3892/etm.2018.6097. View